[go: up one dir, main page]

PE20130814A1 - Sales de benzimidazolil piridil eteres y formulaciones que las contienen - Google Patents

Sales de benzimidazolil piridil eteres y formulaciones que las contienen

Info

Publication number
PE20130814A1
PE20130814A1 PE2013000257A PE2013000257A PE20130814A1 PE 20130814 A1 PE20130814 A1 PE 20130814A1 PE 2013000257 A PE2013000257 A PE 2013000257A PE 2013000257 A PE2013000257 A PE 2013000257A PE 20130814 A1 PE20130814 A1 PE 20130814A1
Authority
PE
Peru
Prior art keywords
acid
crossed
weight
formulations containing
cross
Prior art date
Application number
PE2013000257A
Other languages
English (en)
Inventor
Rampurna Gullapalli
Ahmad Hashash
Piotr H Karpinski
Kangwen L Lin
Eric M Loeser
Augustus O Okhamafe
Paul Allen Sutton
Eduardo Sy
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20130814A1 publication Critical patent/PE20130814A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE a) UNA SAL ACIDA {1-METIL-5-[2-(5-TRIFLUOROMETIL-1H-IMIDAZOL-2-IL)-PIRIDIN-4-ILOXI]-1H-BENZOIMIDAZOL-2-IL}-(4-TRIFLUOROMETIL-FENIL)AMINA SELECCIONADO DEL GRUPO ACIDO ASCORBICO, ACIDO MALICO, ACIDO OXALICO, ACIDO LACTICO ENTRE OTROS, EN UNA CANTIDAD DE 0,01%-80% EN PESO; b)AGENTE TENSIOACTIVO SELECCIONADO DE ESTEARATO DE POLIOXIL 40, SUCCINATO DE d-ALFA-TOCOFERIL POLIETILENGLICOL 1000 Y POLOXAMERO 188, EN UNA CANTIDAD DE 0,01%-60% EN PESO; c) VEHICULO SELLECIONADO DEL GRUPO DE POVIDONA ENTRECRUZADA, DEXTRANO ENTRECRUZADO, HIDROXIPROPILMETILCELULOSA, ENTRE OTROS; d) ADEMAS COMPRENDE ANTIOXIDANTE, AGENTE COLORANTE, AGENTE SABORIZANTE, CONSERVANTE Y ENDULZANTE. REFERIDA ADEMAS A UN PROCESO FARMACEUTICA. DICHOS COMPUESTOS SON UTILES PARA EL TRATAMIENTO DE CANCER.
PE2013000257A 2006-08-30 2007-08-29 Sales de benzimidazolil piridil eteres y formulaciones que las contienen PE20130814A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84117706P 2006-08-30 2006-08-30
US95446607P 2007-08-07 2007-08-07

Publications (1)

Publication Number Publication Date
PE20130814A1 true PE20130814A1 (es) 2013-08-08

Family

ID=39027583

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2007001169A PE20080766A1 (es) 2006-08-30 2007-08-29 Sales de benzimidazolil piridil eteres y formulaciones que las contienen
PE2013000257A PE20130814A1 (es) 2006-08-30 2007-08-29 Sales de benzimidazolil piridil eteres y formulaciones que las contienen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2007001169A PE20080766A1 (es) 2006-08-30 2007-08-29 Sales de benzimidazolil piridil eteres y formulaciones que las contienen

Country Status (33)

Country Link
US (2) US8202998B2 (es)
EP (1) EP2059518B1 (es)
JP (1) JP5279712B2 (es)
KR (1) KR20090043542A (es)
CN (1) CN101516870B (es)
AT (1) ATE504584T1 (es)
AU (1) AU2007290388B2 (es)
BR (1) BRPI0716243A2 (es)
CA (1) CA2660376C (es)
CL (1) CL2007002533A1 (es)
CO (1) CO6150180A2 (es)
CY (1) CY1112187T1 (es)
DE (1) DE602007013774D1 (es)
DK (1) DK2059518T3 (es)
ES (1) ES2360968T3 (es)
GT (1) GT200900045A (es)
HR (1) HRP20110311T1 (es)
IL (1) IL196811A (es)
JO (1) JO2702B1 (es)
MA (1) MA30711B1 (es)
MX (1) MX2009002279A (es)
MY (1) MY161829A (es)
NO (1) NO20091236L (es)
NZ (1) NZ574620A (es)
PE (2) PE20080766A1 (es)
PL (1) PL2059518T3 (es)
PT (1) PT2059518E (es)
RU (1) RU2457206C2 (es)
SI (1) SI2059518T1 (es)
TN (1) TN2009000068A1 (es)
TW (1) TW200819438A (es)
WO (1) WO2008027523A2 (es)
ZA (1) ZA200900664B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080766A1 (es) * 2006-08-30 2008-06-15 Novartis Ag Sales de benzimidazolil piridil eteres y formulaciones que las contienen
WO2008140850A1 (en) * 2007-03-02 2008-11-20 Novartis Ag Solid forms of a raf kinase inhibitor
AU2009257487B2 (en) * 2008-06-13 2013-01-31 Novartis Ag Substituted benzimidazoles for neurofibromatosis
DK2391366T3 (da) * 2009-01-29 2013-01-07 Novartis Ag Substituerede benzimidazoler til behandling af astrocytomer
WO2011044072A1 (en) 2009-10-05 2011-04-14 Novartis Ag Combination of raf-265 and an activator of ampk for use in the treatment of a proliferative disease
PH12013501098A1 (en) * 2010-12-03 2013-07-08 Novartis Ag Pharmaceutical compositions
WO2021110697A1 (en) * 2019-12-02 2021-06-10 Astrazeneca Ab Solid pharmaceutical formulations of 6-(2-chloro-6-methylpyridin-4-yl)-5-(-4-fluorophenyl)-1,2,4-triazin-3-amine
CN114478519B (zh) * 2020-10-23 2024-06-11 励缔(杭州)医药科技有限公司 吡唑并吡啶类化合物或其盐及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299108B2 (en) * 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
JP4628678B2 (ja) 2002-03-29 2011-02-09 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 置換ベンズアゾールおよびＲａｆキナーゼ阻害剤としてのそれらの使用
US20060189619A1 (en) 2005-02-24 2006-08-24 Wyeth 3-({4-[2-(4-Tert-butylphenyl)-1h-benzimidazol-4-yl]piperazin-1-yl}methyl)pyrido[2,3-b]]pyrazi ne compounds
PE20070427A1 (es) * 2005-08-30 2007-04-21 Novartis Ag Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
US7731795B2 (en) 2005-12-02 2010-06-08 Clemson University Rhombohedral fluoroberyllium borate crystals and hydrothermal growth thereof for use in laser and non-linear optical applications and devices
DK2046292T3 (da) * 2006-07-21 2010-06-07 Novartis Ag Formuleringer for benzimidazolylpyridylethere
PE20080766A1 (es) * 2006-08-30 2008-06-15 Novartis Ag Sales de benzimidazolil piridil eteres y formulaciones que las contienen

Also Published As

Publication number Publication date
NO20091236L (no) 2009-03-27
US20120308651A1 (en) 2012-12-06
EP2059518A2 (en) 2009-05-20
DK2059518T3 (da) 2011-05-16
JP2010502622A (ja) 2010-01-28
US20100168060A1 (en) 2010-07-01
CN101516870B (zh) 2013-09-11
HRP20110311T1 (hr) 2011-08-31
HK1131613A1 (en) 2010-01-29
CO6150180A2 (es) 2010-04-20
ES2360968T3 (es) 2011-06-10
MY161829A (en) 2017-05-15
BRPI0716243A2 (pt) 2013-09-03
US8202998B2 (en) 2012-06-19
IL196811A (en) 2013-03-24
ATE504584T1 (de) 2011-04-15
AU2007290388A1 (en) 2008-03-06
CA2660376A1 (en) 2008-03-06
AU2007290388B2 (en) 2011-07-14
MA30711B1 (fr) 2009-09-01
ZA200900664B (en) 2009-12-30
CY1112187T1 (el) 2015-12-09
IL196811A0 (en) 2009-11-18
MX2009002279A (es) 2009-03-20
DE602007013774D1 (de) 2011-05-19
PE20080766A1 (es) 2008-06-15
SI2059518T1 (sl) 2011-06-30
NZ574620A (en) 2011-05-27
TW200819438A (en) 2008-05-01
RU2009111384A (ru) 2010-10-10
PL2059518T3 (pl) 2011-09-30
RU2457206C2 (ru) 2012-07-27
GT200900045A (es) 2010-06-14
CA2660376C (en) 2014-04-15
TN2009000068A1 (en) 2010-08-19
CL2007002533A1 (es) 2008-02-08
WO2008027523A3 (en) 2008-04-10
JO2702B1 (en) 2013-03-03
KR20090043542A (ko) 2009-05-06
PT2059518E (pt) 2011-07-11
WO2008027523A2 (en) 2008-03-06
CN101516870A (zh) 2009-08-26
US8501785B2 (en) 2013-08-06
JP5279712B2 (ja) 2013-09-04
EP2059518B1 (en) 2011-04-06

Similar Documents

Publication Publication Date Title
PE20130814A1 (es) Sales de benzimidazolil piridil eteres y formulaciones que las contienen
ES2540853T3 (es) Sales de dicetopiperazina para la administración de fármacos
JP5372523B2 (ja) 真菌症治療用ゲル組成物
JP5160409B2 (ja) 外用の医薬組成物
MX2010010647A (es) Proceso para preparar formulaciones de dabigatran para administracion oral.
EA201070588A1 (ru) Производные 1,2,3-триазола для применения в качестве ингибиторов стеароил-соа десатуразы
PE20191755A1 (es) Derivados de pirazol como inhibidores de malt 1
MX2009004475A (es) Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma.
UY29562A1 (es) Compuestos heterocíclicos de amino benzoilo, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
EA201071094A1 (ru) Тризамещенные 1,2,4-триазолы в качестве модуляторов никотиновых ацетилхолиновых рецепторов
CO6220902A2 (es) Formulacion en polvo del valganciclovir
CL2008002316A1 (es) Compuestos heterociclicos nitrogenados que contienen fenilendiamina sustituida, inhibidores de la interaccion entre mdm2 y p53; procedimiento de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento del cancer.
CO6270302A2 (es) Formulaciones solidas de liberacion rapida que incluyen florfenicol y sales farmaceuticamente aceptables del mismo.
RU2015146957A (ru) Производные доластатина 10 и ауристатинов
CU24330B1 (es) Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral)
CO2019004190A2 (es) Formulaciones liposomales para uso en el tratamiento del cáncer
PH12017500136A1 (en) Long-chain dimethylaniline derivative compounds, their preparation methods, self-assembled textures, and uses thereof
BR112013007343A2 (pt) métodos para tratar eritema associado com rosácea e para tratar telangiectasia associada com rosácea, e, composição tópica
PE20151607A1 (es) Formulaciones de compuestos organicos
RU2008110644A (ru) Применение производных глутаровой кислоты или их фармацевтически приемлемых солей в качестве противоаритмических средств
CO2022008616A2 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
PH12014501181A1 (en) N- (4 -quinolinylmethyl) sulfonamide derivatives and their use as anthelmintics
JOP20220202A1 (ar) تركيبة صيدلانية تشمل مركب مشتق من بنزيميدازول
AR085273A1 (es) Formulacion liquida libre de propelente que comprende una droga antimuscarinica

Legal Events

Date Code Title Description
FA Abandonment or withdrawal